NO20000935L - Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei - Google Patents

Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Info

Publication number
NO20000935L
NO20000935L NO20000935A NO20000935A NO20000935L NO 20000935 L NO20000935 L NO 20000935L NO 20000935 A NO20000935 A NO 20000935A NO 20000935 A NO20000935 A NO 20000935A NO 20000935 L NO20000935 L NO 20000935L
Authority
NO
Norway
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
NO20000935A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000935D0 (no
Inventor
Rekha Gupta-Bansal
Kurt R Brunden
James B Parent
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Publication of NO20000935D0 publication Critical patent/NO20000935D0/no
Publication of NO20000935L publication Critical patent/NO20000935L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
NO20000935A 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei NO20000935L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26
PCT/US1998/017500 WO1999010009A1 (fr) 1997-08-26 1998-08-24 Procede d'inhibition d'activation de complement par la voie alterne

Publications (2)

Publication Number Publication Date
NO20000935D0 NO20000935D0 (no) 2000-02-25
NO20000935L true NO20000935L (no) 2000-04-18

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000935A NO20000935L (no) 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Country Status (13)

Country Link
US (3) US6333034B1 (fr)
EP (1) EP1007092B1 (fr)
JP (1) JP2001513576A (fr)
AT (1) ATE335511T1 (fr)
AU (1) AU756490B2 (fr)
CA (1) CA2302317A1 (fr)
DE (1) DE69835524T2 (fr)
DK (1) DK1007092T3 (fr)
ES (1) ES2270530T3 (fr)
NO (1) NO20000935L (fr)
NZ (1) NZ503033A (fr)
PT (1) PT1007092E (fr)
WO (1) WO1999010009A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
EP2896631A1 (fr) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition de l'activation du complément C5 pour le traitement et la prévention d'un rejet de xénogreffe retardée ou d'un rejet vasculaire aigu.
WO2003009803A2 (fr) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Procede d'amelioration de la fonction cognitive
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
EP1737487B1 (fr) * 2004-03-30 2016-05-25 Canadian Blood Services Methode servant a traiter des maladies auto-immunes au moyen d'anticorps
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
WO2006128006A1 (fr) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition de la voie de complement alternative pour le traitement de lesions traumatiques du cerveau, de lesions de la moelle epiniere et de conditions apparentees
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP2073898A1 (fr) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Inhibition du complément pour une régénération améliorée des nerfs
TW201716437A (zh) * 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2008154018A2 (fr) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Modulation de properdine de voie alternative et ses utilisations
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
DK2262831T3 (en) * 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
US20110262456A1 (en) * 2008-11-14 2011-10-27 Rekha Bansal Method of treating ischemia reperfusion injury
WO2011003098A1 (fr) 2009-07-02 2011-01-06 Musc Foundation For Research Development Procédés de stimulation de la régénération du foie
EP2544694B1 (fr) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. Procédé pour l'inhibition de troubles à médiation par la voie alternative par des anticorps anti-properdine qui inhibent les interactions de c5 avec la properdine
CA2811221C (fr) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Anticorps anti-properdine humanises et chimeriques
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
EP3524258B1 (fr) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Méthodes de traitement de troubles chroniques au moyen d'inhibiteurs de complément
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
CA2869477C (fr) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Anticorps anti-facteur c3 humanises et chimeriques, et leurs utilisations
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CA2887050A1 (fr) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Anticorps specifiques de voies alternatives pour traiter les maladies hemolytiques
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017127761A1 (fr) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions et procédés pour inhiber le facteur d
EP3275897A1 (fr) * 2016-07-27 2018-01-31 Biotest AG Procédé de préparation de compositions d'immunoglobuline
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
DE69533921T2 (de) * 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs

Also Published As

Publication number Publication date
ATE335511T1 (de) 2006-09-15
US20020015701A1 (en) 2002-02-07
AU756490B2 (en) 2003-01-16
DK1007092T3 (da) 2006-10-02
AU9203398A (en) 1999-03-16
EP1007092B1 (fr) 2006-08-09
PT1007092E (pt) 2006-12-29
NZ503033A (en) 2003-01-31
US20030198636A1 (en) 2003-10-23
JP2001513576A (ja) 2001-09-04
CA2302317A1 (fr) 1999-03-04
DE69835524T2 (de) 2007-04-05
US6333034B1 (en) 2001-12-25
ES2270530T3 (es) 2007-04-01
DE69835524D1 (de) 2006-09-21
WO1999010009A1 (fr) 1999-03-04
EP1007092A1 (fr) 2000-06-14
NO20000935D0 (no) 2000-02-25

Similar Documents

Publication Publication Date Title
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
BG101833A (bg) Гуаниново производно
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
BR9612297A (pt) Método de produção de 1,1,1,3,3-pentafluorpropano
IS4147A (is) Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
NO971645L (no) Fremgangsmåte for fremstilling av derivater av 4a,5,9,10,11,12,-heksahydro-6H-benzofuro£3a,3,2-ef|£2|-benzacepin
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
NO981800L (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
TR199601005A2 (tr) Uzun zincirli, dallanmis poliolefinlerin üretimi icin yöntem.
AU2895397A (en) Novel substance library and supramolecular complexes prepared therewith
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
BG103649A (en) Method for the preparation of eprosartan
FI960937A7 (fi) Menetelmä aryylialkyylihydroperoksidien valmistamiseksi
BG103650A (en) Method for the preparation of eprosartan
NO990450D0 (no) Behandling av sinnslidelser
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
PL356523A1 (en) Substituted 1 and 2 naphthol mannich bases
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
ZA995559B (en) Improved process for the production of an n-acyl derivative of O,S-dialkyl phosphoroamidothioate.
NZ310180A (en) Process for the synthesis of benzo[b]thiophenes, in particular 2-aryl-benzo[b]thiophenes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application